



Final Appraisal Recommendation

Advice number: 0522 – February 2022

Buprenorphine (Sixmo®) 74.2 mg implant

Submission by Accord Healthcare

Recommendation of the All Wales Medicines Strategy Group

Buprenorphine (Sixmo®) is not recommended for use within NHS Wales for the substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

The case for clinical effectiveness and cost-effectiveness has not been proven.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4262), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
0522:

Buprenorphine (Sixmo®) 74.2 mg implant. February 2022